Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Lyell Immunopharma, Inc. (LYEL)

3.87   -0.06 (-1.53%) 12-06 09:31
Open: 4.03 Pre. Close: 3.93
High: 3.94 Low: 3.87
Volume: 3,987 Market Cap: 965(M)

Technical analysis

as of: 2022-12-06 9:20:14 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 6.17     One year: 7.19
Support: Support1: 3.86    Support2: 3.21
Resistance: Resistance1: 5.28    Resistance2: 6.15
Pivot: 4.26
Moving Average: MA(5): 4.06     MA(20): 4.44
MA(100): 6.3     MA(250): 6.03
MACD: MACD(12,26): -0.5     Signal(9): -0.6
Stochastic oscillator: %K(14,3): 5.9     %D(3): 6.9
RSI: RSI(14): 27.7
52-week: High: 10.26  Low: 3.56
Average Vol(K): 3-Month: 1,153 (K)  10-Days: 962 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ LYEL ] has closed above bottom band by 9.9%. Bollinger Bands are 55.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.05 - 4.07 4.07 - 4.09
Low: 3.82 - 3.84 3.84 - 3.86
Close: 3.89 - 3.93 3.93 - 3.97

Company Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Headline News

Thu, 01 Dec 2022
2022-12-01 | NDAQ:LYEL | Press Release | Lyell Immunopharma Inc. - Stockhouse

Tue, 29 Nov 2022
What is the Market's View on Lyell Immunopharma Inc (LYEL) Stock's Price and Volume Trends Tuesday? - InvestorsObserver

Wed, 16 Nov 2022
Where Will Lyell Immunopharma Inc (LYEL) Stock Go Next After It Is Down 0.45% in a Week? - InvestorsObserver

Wed, 09 Nov 2022
Does Lyell Immunopharma Inc (LYEL) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver

Mon, 07 Nov 2022
Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors - GlobeNewswire

Tue, 25 Oct 2022
Healthcare Stocks Moving Tuesday: TSHA, RNLX, MEDP, CGC, LYEL, PXMD, IMRA, BEAT - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 249 (M)
Shares Float 142 (M)
% Held by Insiders 18 (%)
% Held by Institutions 63.6 (%)
Shares Short 18,990 (K)
Shares Short P.Month 18,270 (K)

Stock Financials

EPS 1.47
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.28
Profit Margin (%) 0
Operating Margin (%) -559.2
Return on Assets (ttm) -12.6
Return on Equity (ttm) -28.7
Qtrly Rev. Growth -100
Gross Profit (p.s.) 0.04
Sales Per Share 0.15
EBITDA (p.s.) -0.81
Qtrly Earnings Growth 0
Operating Cash Flow -163 (M)
Levered Free Cash Flow -73 (M)

Stock Valuations

PE Ratio 2.67
PEG Ratio 0.5
Price to Book value 1.19
Price to Sales 25.04
Price to Cash Flow -6.03

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.